Wells Fargo
TRVI icon

Wells Fargo’s Trevi Therapeutics TRVI Stock Holding History

Wells Fargo’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Buy
114,707
+76,651
+201% +$1.11M ﹤0.01% 3548
2026
Q1 		$454K Sell
38,056
-63,223
-62% -$708K ﹤0.01% 4233
2025
Q4 		$1.27M Buy
101,279
+45,593
+82% +$527K ﹤0.01% 3783
2025
Q3 		$510K Buy
55,686
+14,515
+35% +$109K ﹤0.01% 4289
2025
Q2 		$225K Buy
41,171
+75
+0.2% +$467 ﹤0.01% 4707
2025
Q1 		$258K Buy
41,096
+8,046
+24% +$38.4K ﹤0.01% 4525
2024
Q4 		$136K Buy
33,050
+9,562
+41% +$30.6K ﹤0.01% 5022
2024
Q3 		$78.4K Buy
23,488
+10
+0% +$30 ﹤0.01% 5152
2024
Q2 		$70K Buy
23,478
+6,639
+39% +$18.4K ﹤0.01% 5144
2024
Q1 		$58.1K Buy
16,839
+3,877
+30% +$8.65K ﹤0.01% 5193
2023
Q4 		$17.4K Buy
12,962
+2,687
+26% +$4.07K ﹤0.01% 5686
2023
Q3 		$22.4K Sell
10,275
-5,562
-35% -$12.6K ﹤0.01% 5552
2023
Q2 		$37.9K Buy
15,837
+15,572
+5,876% +$39.2K ﹤0.01% 5532
2023
Q1 		$490 Buy
265
+4
+2% +$9 ﹤0.01% 6562
2022
Q4 		$504 Buy
261
+122
+88% +$240 ﹤0.01% 6385
2022
Q3 		$0 Sell
139
-27
-16% -$89 ﹤0.01% 7386
2022
Q2 		$0 Buy
166
+93
+127% +$228 ﹤0.01% 7504
2022
Q1 		$0 Hold
73
– – ﹤0.01% 7823
2021
Q4 		$0 Buy
73
+27
+59% +$28 ﹤0.01% 7816
2021
Q3 		$0 Buy
46
+13
+39% +$23 ﹤0.01% 7529
2021
Q2 		$0 Buy
33
+9
+38% +$20 ﹤0.01% 7449
2021
Q1 		$0 Buy
24
+2
+9% +$6 ﹤0.01% 7384
2020
Q4 		$0 Hold
22
– – ﹤0.01% 7027
2020
Q3 		$0 Sell
22
-14
-39% -$66 ﹤0.01% 6909
2020
Q2 		$0 Hold
36
– – ﹤0.01% 6831
2020
Q1 		$0 Buy
+36
New +$164 ﹤0.01% 6811

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Wells Fargo's TRVI Position: Q2 2026 in Review

Wells Fargo increased its Trevi Therapeutics (TRVI) stake by 201% in Q2 2026, buying an estimated $1.11M and bringing the position to 114,707 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3548.

Wells Fargo first reported a position in TRVI in Q1 2020 and has held it in 26 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Wells Fargo held 114,707 shares of Trevi Therapeutics worth $2.14M as of Q2 2026.
  • Wells Fargo bought 76,651 Trevi Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Trevi Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3548 holding.
  • Wells Fargo first reported a position in Trevi Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.